Sue Wallcraft is a member of the Audit and Risk Management Committee and the Remuneration Committee. Sue is an experienced general counsel and company secretary with over 25 years’ experience in the pharmaceutical industry and health charities. She is a qualified English solicitor and brings significant legal and governance knowledge to the board. Sue is currently General Counsel and Company Secretary for Vernalis (R&D) Limited, a non-executive director of Medicines Discovery Catapult.
Susan Wallcraft
Latest news
-
LifeArc launches £40m research centres that will unlock new tests, treatments and cures for people living with rare diseases
Read more: LifeArc launches £40m research centres that will unlock new tests, treatments and cures for people living with rare diseases -
First-of-a-kind plan announced to get more children access to cutting-edge, proven gene therapy treatments for rare diseases
Read more: First-of-a-kind plan announced to get more children access to cutting-edge, proven gene therapy treatments for rare diseases -
New £6.2m partnership will help to eliminate a deadly disease affecting children and vulnerable people in Kenya
Read more: New £6.2m partnership will help to eliminate a deadly disease affecting children and vulnerable people in Kenya